This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A. HAUT, M.D.; S. J. ALTMAN, M.D.; G. E. CARTWRIGHT, M.D.; M. M. WINTROBE, M.D.

AMA Arch Intern Med. 1955;96(4):451-462.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

A sulfonic acid ester, Myleran (1,4-bis [methylsulfonyloxy] (Fig. 1), synthesized by Timmis,¹ was introduced by Galton ² for the treatment of chronic myelocytic leukemia. This agent appears to be so promising that it seemed worth while to publish a full account of our own experience with it. Preliminary findings in some of our cases have been reported already.³ In addition to the latter and the 19 patients treated by Galton,² the results of treatment of only 40 other cases have been reported until now.*

MATERIAL

Since November, 1952. we have used Myleran in the treatment of 16 consecutive cases of chronic myelocytic leukemia (Table 1). Eleven had received no previous therapy; five cases had been treated earlier with x-rays, nitrogen mustard, triethylenemelamine, or radioactive phosphorus. The interval from the apparent onset of leukemia to the start of Myleran therapy ranged from 1 month to 56 months; in seven cases it . . . [Full Text PDF of this Article]

Author Affiliations
Salt Lake City

From the Department of Medicine, University of Utah College of Medicine, American Cancer Society Clinical Fellow (Dr. Haut and Dr. Altman).

Footnotes
Submitted for publication June 27, 1955.

This investigation was supported by a research grant (C-2349) from the National Cancer Institute, National Institutes of Health, Public Health Service.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?